Can enbrel be used for ankylosing spondylitis?

Can Enbrel treat ankylosing spondylitis?

Enbrel is approved for treating ankylosing spondylitis. It works by blocking TNF-alpha, a protein that drives inflammation in the spine and joints. Clinical studies showed it improves pain, stiffness, and function in people with this condition.

How does Enbrel work for ankylosing spondylitis?

Enbrel binds to TNF-alpha and prevents it from attaching to its receptors. This reduces inflammation inside the spinal column and stops further damage to joints. Patients often report less back pain and improved mobility after several weeks of treatment.

What side effects do patients report with Enbrel for ankylosing spondylitis?

Patients using Enbrel for this condition complain about injection site reactions, upper respiratory infections, and headaches. Serious risks include increased chance of serious infections, tuberculosis reactivation, and some types of cancer. Doctors usually screen for tuberculosis before starting Enbrel.

Can older treatments be compared with Enbrel for ankylosing spondylitis?

NSAIDs remain the first-line option for many patients. They relieve pain but do not modify disease progression. Enbrel and other TNF inhibitors offer disease-modifying effects and may prevent spinal fusion over langfristig. Some patients who fail NSAIDs move directly to biologics like Enbrel.

When does Enbrel’s patent expire?

Enbrel’s patent expires in 2029. Biosimilars may appear after that date. The company maintains several secondary patents that delay generic entry until 2029.